Nicotine containing formulation
Disclosed is nicotine containing solid oral transmucosal dosage forms containing a therapeutically effective amount of nicotine polacrilex, citric acid monohydrate, sucrose and liquid glucose. The dosage form is preferably in the form of lozenge.
1. A lozenge for transmucosal delivery consisting of 10 mg of nicotine polacrilex, 20 mg citric acid monohydrate, 1597 mg sucrose, 1024 mg liquid glucose, 2.5 mg mentha piperita, and a pharmaceutically acceptable coloring agent.
2. A lozenge for transmucosal delivery consisting of 20 mg of nicotine polacrilex, 20 mg citric acid monohydrate, 1590 mg sucrose, 1020 mg liquid glucose, 2.5 mg mentha piperita, and a pharmaceutically acceptable coloring agent.
3. A lozenge for transmucosal delivery consisting of 10 mg of nicotine polacrilex, 20 mg citric acid monohydrate, 1590 mg sucrose, 1020 mg maltitol syrup, 2.5 mg mentha piperita, and a pharmaceutically acceptable coloring agent.
4. A lozenge for transmucosal delivery consisting of 10 mg of nicotine polacrilex, 20 mg citric acid monohydrate, 1597 mg sucrose, 1024 mg maltitol syrup, 2.5 mg mentha piperita, and a pharmaceutically acceptable coloring agent.
5. A lozenge for transmucosal delivery consisting of 10 mg of nicotine polacrilex, 20 mg citric acid monohydrate, 2461.98 mg isomalt, 2.75 mg aspartame, 2.75 mg acesulfame potassium, 2.5 mg mentha piperita, and a pharmaceutically acceptable coloring agent.
6. A lozenge for transmucosal delivery consisting of 20 mg of nicotine polacrilex, 20 mg citric acid monohydrate, 2451.96 mg isomalt, 2.75 mg aspartame, 2.75 mg acesulfame potassium, 2.5 mg mentha piperita, and a pharmaceutically acceptable coloring agent.
7. A lozenge prepared by sizing a solid mass for transmucosal delivery consisting of (a) 10 mg of nicotine polacrilex, (b) 20 mg citric acid monohydrate, (c) a sugar syrup consisting of 1597 mg sucrose and 1024 mg liquid glucose, (d) 2.5 mg mentha piperita, and (e) a pharmaceutically acceptable coloring agent, wherein the lozenge provides single phase release of the nicotine.
8. A lozenge prepared by sizing a solid mass for transmucosal delivery consisting of (a) 10 or 20 mg of nicotine polacrilex, (b) 20 mg citric acid monohydrate, (c) a sugar syrup consisting of 1590 mg sucrose and 1020 mg liquid glucose, (d) 2.5 mg mentha piperita, and (e) a pharmaceutically acceptable coloring agent, wherein the lozenge provides single phase release of the nicotine.